$Editas Medicine, Inc. Common Stock(EDIT)$ One need only look at the bumpy trajectories of other promising drug-making strategies, like RNA interference or gene therapy, to see what could be in store. It took decades of research, clinical testing, and some devastating setbacks for gene therapy to be where it is today—and it’s still got just one approved product in Europe. RNAi was discovered in 1998, and is still at least a year away from its first product, a therapy being developed by Alnylam Pharmaceuticals.